The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
WB: Use at a concentration of 2 - 6 µg/ml. Detects a band of approximately 220 kDa (predicted molecular weight: 222 kDa). A 50kDa unknown band can also be detected.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Histone acetyltransferase that acetylates lysine residues in histone H3 and histone H4 (in vitro). Component of the MOZ/MORF complex which has a histone H3 acetyltransferase activity. May act as a transcriptional coactivator for RUNX1 and RUNX2.
Involvement in disease
Note=Chromosomal aberrations involving MYST3 may be a cause of acute myeloid leukemias. Translocation t(8;16)(p11;p13) with CREBBP; translocation t(8;22)(p11;q13) with EP300. MYST3-CREBBP may induce leukemia by inhibiting RUNX1-mediated transcription. Inversion inv(8)(p11;q13) generates the MYST3-NCOA2 oncogene, which consists of the N-terminus part of MYST3/MOZ and the C-terminus part of NCOA2/TIF2. MYST3-NCOA2 binds to CREBBP and disrupts its function in transcription activation. Note=A chromosomal aberration involving MYST3 is a cause of therapy-related myelodysplastic syndrome. Translocation t(2;8)(p23;p11.2) with ASXL2 generates a MYST3-ASXL2 fusion protein.
References for Anti-Histone acetyltransferase MYST3 antibody (ab41718)
This product has been referenced in:
Paggetti J et al. Crosstalk between leukemia-associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34+ cells. Oncogene29:5019-31 (2010).
Read more (PubMed: 20581860) »